Selling Shareholder Offers 2.45M Shares Amidst Delisting Concerns

summarizeSummary

A selling shareholder is offering 2.45 million shares, valued at approximately $1.8 million, representing 20% of Evogene's market cap, intensifying pressure on the distressed company already facing delisting and going concern doubts.

check_boxKey Events

• Significant Share Resale

  A selling shareholder is offering 2,446,707 ordinary shares. Based on the last reported sale price of $0.74 per share (May 19, 2026), this offering is valued at approximately $1.8 million, representing about 20% of the company's current market capitalization.

• No Proceeds to Company

  The company will not receive any proceeds from the sale of these shares, as they are being offered by an existing shareholder.

• Distressed Company Context

  This significant offering occurs while Evogene is trading near its 52-week low, faces a Nasdaq delisting notice, and has disclosed substantial doubt about its ability to continue as a going concern. The company also recently reported a wider net loss and lower revenue in Q1 2026.

auto_awesomeAnalysis

A selling shareholder is offering 2.45 million ordinary shares, valued at approximately $1.8 million, which represents a substantial 20% of Evogene's current market capitalization. This significant increase in market supply from an institutional investor adds considerable selling pressure and market overhang, particularly as the company is already facing Nasdaq delisting, has expressed substantial doubt about its ability to continue as a going concern, and recently reported a wider net loss and lower revenue in Q1 2026. The company will not receive any proceeds from this resale.